Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension-Reference-Cited by-全球学者库

Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension

Published:2017 Issue:9 Volume:81 Page:1360-1367
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Tanabe Nobuhiro¹,Ikeda Satoshi²,Tahara Nobuhiro³,Fukuda Keiichi⁴,Hatano Masaru⁵,Ito Hiroshi⁶,Nakayama Tomotaka⁷,Anzai Toshihisa⁸,Hashimoto Akiyoshi⁹,Inoue Teruo¹⁰,Kajinami Kouji¹¹,Kihara Yasuki¹²,Kinoshita Hideyuki¹³,Kuwahara Koichiro¹⁴,Murohara Toyoaki¹⁵,Okazaki Osamu¹⁶,Sakai Satoshi¹⁷,Satoh Toru¹⁸,Takeda Yutaka¹⁹,Takeishi Yasuchika²⁰,Taniguchi Mitsugu²¹,Watanabe Hiroshi²²,Yamamoto Takeshi²³,Yamauchi-Takihara Keiko²⁴,Yoshioka Koichiro²⁵,Sasayama Shigetake²⁶

Affiliation:

1. Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University

2. Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences

3. Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine

4. Department of Cardiology, Keio University School of Medicine

5. Department of Therapeutic Strategy for Heart Failure, The University of Tokyo Hospital

6. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine

7. Department of Pediatrics, Toho University Omori Medical Center

8. Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center

9. Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University Hospital

10. Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine

11. Department of Cardiology, Kanazawa Medical University

12. Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences

13. Department of Community Medicine Supporting System, Kyoto University Graduate School of Medicine

14. Department of Cardiovascular Medicine, Shinshu University School of Medicine

15. Department of Cardiology, Nagoya University Graduate School of Medicine

16. Department of Cardiology, National Center for Global Health and Medicine

17. Cardiovascular Division, Department of Clinical Medicine, Faculty of Medicine, University of Tsukuba

18. Division of Cardiology Department of Medicine, Kyorin University Hospital

19. Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences

20. Department of Cardiovascular Medicine, Fukushima Medical University

21. Department of Cardiology, Osaka Pref. Saiseikai Tondabayashi Hospital

22. Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine

23. Faculty of Health Science, Yamaguchi University Graduate School of Medicine

24. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

25. Graduate School of Medicine, Tokai University

26. Uji Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/81/9/81_CJ-16-1348/_pdf

Reference22 articles.

1. 1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.

2. 2. Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, Galiè N. Treatment of pulmonary hypertension. Lancet Respir Med 2016; 4: 323–336.

3. 3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.

4. 4. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65: 1976–1997.

5. 6. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012; 142: 448–456.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta‐analysis;Animal Models and Experimental Medicine;2023-09-23

2. Outcomes of selexipag for treatment of pulmonary arterial hypertension in an Asian population;Annals of the Academy of Medicine, Singapore;2023-04-27

3. Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension;Pulmonary Circulation;2023-01

4. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients;Frontiers in Cardiovascular Medicine;2022-09-20

5. Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension;Expert Opinion on Drug Safety;2022-04-28